Engineered and Encapsulated Stem Cells for Resected Brain Tumors
用于切除脑肿瘤的工程化和封装干细胞
基本信息
- 批准号:10578780
- 负责人:
- 金额:$ 36.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-03-01 至 2024-02-29
- 项目状态:已结题
- 来源:
- 关键词:AdultAftercareBostonBrain NeoplasmsCD8-Positive T-LymphocytesCancer PatientCell Cycle ArrestCell DeathCell Surface ReceptorsCellsCessation of lifeClinicalClinical EngineeringClinical ResearchCollaborationsDataEncapsulatedEngineeringEnsureExcisionExtracellular MatrixGenerationsGeneticGenetic EngineeringGlioblastomaGoalsHumanHuman EngineeringImmuneImmune EvasionImmune responseImmunohistochemistryImmunotherapyInfiltrationInjection of therapeutic agentInterferon-betaLaboratoriesLigandsMagnetic ResonanceMalignant NeoplasmsMalignant neoplasm of brainMediatingMesenchymal Stem CellsModalityModelingMonoclonal AntibodiesMusMyeloid-derived suppressor cellsNatureOperative Surgical ProceduresPTEN genePatientsPhenotypePlayPositron-Emission TomographyPrimary Brain NeoplasmsPrimary NeoplasmPrognosisProteinsPublishingResectedRoleSafetySimplexvirusSurgically-Created Resection CavityTestingTherapeuticThymidine KinaseTimeTranslatingTreatment EfficacyTumor DebulkingTumor Suppressor ProteinsUp-Regulationadult stem cellbioluminescence imagingcancer typeclinical careclinical translationcytotoxicdesignengineered stem cellsfluorescence imagingimaging biomarkerimmune cell infiltrateimmune checkpoint blockadeimmune modulating agentsimmune resistanceimmunomodulatory therapiesimmunoregulationin vivomouse modelmutantneoplastic cellneuropathologypost-transplantpreventprogrammed cell death protein 1programsreceptorrecruitstem cell fatestem cellstime of flight mass spectrometrytumortumor microenvironmenttumor-immune system interactionstwo photon microscopy
项目摘要
SUMMARY
Glioblastoma (GBM) is the most common primary brain tumor in adults with a very poor prognosis. Given, the
central role tumor resection plays in GBM therapy clinical care, understanding the specific influence of tumor
resection on immune response in the tumor microenvironment offers a new platform for developing effective
immune based therapies for GBM. We have recently developed syngeneic orthotopic mouse GBM-model of
tumor resection and shown that tumor debulking results in substantial reduction of myeloid-derived suppressor
cells (MDSCs) and simultaneous recruitment of CD4/CD8 T cells into the resection cavity. In this proposal, we
will first generate GBM resection models from genetically distinct currently available mouse GBM lines and
analyze profiles of immune cells infiltrated into tumor microenvironment pre- and post-tumor debulking. While
resection of primary tumor has shown clinical benefit, systemically delivered or direct injection of therapeutic
agents in tumor resection cavities has provided limited additional benefit. In our previous studies, we have
extensively demonstrated that locally delivered receptor targeted engineered adult stem cells have therapeutic
benefits and synthetic extracellular matrix (sECM) encapsulation of stem cells is necessary to prevent their rapid
“wash- out” post-transplantation in mouse GBM tumor resection cavity. In our recently published studies, we
have shown that sECM encapsulated mesenchymal stem cell (MSC) mediated local delivery of bifunctional,
immunomodulatory and cytotoxic protein, interferon (IFN) β enhances selective post-surgical infiltration of CD8 T
cells and directly induces cell-cycle arrest in tumor cells. However, IFNβ has been known to upregulate program
cell death ligand 1 (PD-L1) expression on tumor cells, thus hindering the immunomodulatory function of IFNβ.
Based on the recent findings that: blocking PD-L1 induced by IFNβ treatment eradicates established tumors;
tumor suppressor, phosphatase and tensin homolog (PTEN) loss promotes immune resistance; and our exciting
preliminary data on: MSC-IFNβ mediated upregulation of PD-L1 in vivo; and local delivery of ScFv-PDL1, we will
create bimodal MSC expressing ScFv-PDL1 and IFNβ and test them in syngeneic PTEN wild type (wt.) and
mutant GBM models of resection. To ease clinical translation and ensure safety of our approach, we will
ultimately engineer clinical grade human MSC to co-express ScFv-PDL1/IFN β and HSV-thymidine kinase (TK)
and test our approach in GBM tumors generated from patient derived GBM lines in humanized NSG mice. The
incorporation of genetically engineered imaging markers markers into MSC and GBMs will allow us to follow
MSC fate and efficacy in vivo and thus to fine tune the proposed approaches. The overall goal of this proposal is
thus to immune profile genetically distinct GBM resection models and to assess rationale based therapeutic
efficacy of immunomodulatory agents. Once validated, we will initiate a clinical study in which at the time of brain
tumor surgery, the main tumor mass will be removed and encapsulated bimodal MSC will be introduced to
enhance tumor cell eradication. This will have a major impact in saving the lives of brain cancer patients.
总结
胶质母细胞瘤(GBM)是成人中最常见的原发性脑肿瘤,预后极差。给出了
肿瘤切除术在GBM治疗临床护理中发挥的中心作用,了解肿瘤的具体影响
切除肿瘤微环境中的免疫反应为开发有效的
基于免疫的治疗GBM。我们最近开发了同基因原位小鼠GBM模型,
肿瘤切除术,并显示肿瘤减积导致髓源性抑制因子的实质性减少,
细胞(MDSC)和同时募集CD 4/CD 8 T细胞进入切除腔。在本提案中,我们
将首先从遗传上不同的目前可用的小鼠GBM系产生GBM切除模型,
分析肿瘤减积前后浸润到肿瘤微环境中的免疫细胞的概况。而
切除原发性肿瘤已显示出临床益处,全身递送或直接注射治疗性肿瘤的药物组合物,
在肿瘤切除腔中的药物提供了有限的额外益处。在我们以前的研究中,我们有
广泛证明了局部递送的受体靶向的工程化成体干细胞具有治疗性
干细胞的合成细胞外基质(sECM)包封是必要的,以防止它们的快速生长。
小鼠GBM肿瘤切除腔中移植后的“洗出”。在我们最近发表的研究中,我们
已经显示sECM包封的间充质干细胞(MSC)介导的双功能,
免疫调节和细胞毒性蛋白干扰素(IFN)β增强术后CD 8 T细胞选择性浸润
细胞并直接诱导肿瘤细胞的细胞周期停滞。然而,已知IFNβ上调程序,
细胞死亡配体1(PD-L1)在肿瘤细胞上的表达,从而阻碍IFNβ的免疫调节功能。
基于最近的研究结果:阻断IFNβ治疗诱导的PD-L1可根除已建立的肿瘤;
肿瘤抑制因子,磷酸酶和张力蛋白同源物(PTEN)的损失促进免疫抵抗;和我们令人兴奋的
关于MSC-IFNβ介导的PD-L1体内上调和ScFv-PDL 1局部递送的初步数据,我们将
创建表达ScFv-PDL 1和IFNβ的双峰MSC,并在同基因PTEN野生型(wt.)和
切除的突变GBM模型。为了简化临床翻译并确保我们方法的安全性,我们将
最终工程化临床级人MSC以共表达ScFv-PDL 1/IFN β和HSV-胸苷激酶(TK)
并在人源化NSG小鼠中从患者来源的GBM系产生的GBM肿瘤中测试我们的方法。的
将遗传工程成像标记物标记物掺入MSC和GBM将使我们能够跟踪
MSC在体内的命运和功效,从而微调所提出的方法。本提案的总体目标是
因此,免疫概况遗传上不同的GBM切除模型,并评估基于治疗的基本原理,
免疫调节剂的功效。一旦证实,我们将启动一项临床研究,在大脑
在肿瘤手术中,主要肿瘤块将被移除,并且包封的双峰MSC将被引入,
增强肿瘤细胞根除。这将对挽救脑癌患者的生命产生重大影响。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
NK cells in the brain: implications for brain tumor development and therapy.
- DOI:10.1016/j.molmed.2021.12.008
- 发表时间:2022-03
- 期刊:
- 影响因子:13.6
- 作者:Balatsoukas A;Rossignoli F;Shah K
- 通讯作者:Shah K
Engineered cell-based therapies in ex vivo ready-made CellDex capsules have therapeutic efficacy in solid tumors.
- DOI:10.1016/j.biopha.2023.114665
- 发表时间:2023-06
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Immune Profiling of Syngeneic Murine and Patient GBMs for Effective Translation of Immunotherapies.
- DOI:10.3390/cells10030491
- 发表时间:2021-02-25
- 期刊:
- 影响因子:6
- 作者:Khalsa JK;Shah K
- 通讯作者:Shah K
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Khalid A Shah其他文献
Khalid A Shah的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Khalid A Shah', 18)}}的其他基金
Targeting metastatic tumors with engineered cellular therapies
通过工程细胞疗法靶向转移性肿瘤
- 批准号:
10774430 - 财政年份:2023
- 资助金额:
$ 36.39万 - 项目类别:
Gene Edited and Engineered Tumor Cell Therapeutics for Cancer
基因编辑和工程化肿瘤细胞治疗癌症
- 批准号:
10184164 - 财政年份:2021
- 资助金额:
$ 36.39万 - 项目类别:
Gene Edited and Engineered Tumor Cell Therapeutics for Cancer
基因编辑和工程化肿瘤细胞治疗癌症
- 批准号:
10386860 - 财政年份:2021
- 资助金额:
$ 36.39万 - 项目类别:
Gene Edited and Engineered Tumor Cell Therapeutics for Cancer
基因编辑和工程化肿瘤细胞治疗癌症
- 批准号:
10589097 - 财政年份:2021
- 资助金额:
$ 36.39万 - 项目类别:
Engineered and Encapsulated Stem Cells for Resected Brain Tumors
用于切除脑肿瘤的工程化和封装干细胞
- 批准号:
10355476 - 财政年份:2019
- 资助金额:
$ 36.39万 - 项目类别:
Fate and efficacy of targeted therapies for metastatic tumors
转移性肿瘤靶向治疗的命运和疗效
- 批准号:
9176644 - 财政年份:2016
- 资助金额:
$ 36.39万 - 项目类别:
Fate and efficacy of targeted therapies for metastatic tumors
转移性肿瘤靶向治疗的命运和疗效
- 批准号:
9428627 - 财政年份:2016
- 资助金额:
$ 36.39万 - 项目类别:
In vivo imaging of encapsulated stem cells in mouse models of tumor resection
肿瘤切除小鼠模型中封装干细胞的体内成像
- 批准号:
8599446 - 财政年份:2013
- 资助金额:
$ 36.39万 - 项目类别:
In vivo imaging of encapsulated stem cells in mouse models of tumor resection
肿瘤切除小鼠模型中封装干细胞的体内成像
- 批准号:
9405283 - 财政年份:2013
- 资助金额:
$ 36.39万 - 项目类别:
In vivo imaging of encapsulated stem cells in mouse models of tumor resection
肿瘤切除小鼠模型中封装干细胞的体内成像
- 批准号:
8421265 - 财政年份:2013
- 资助金额:
$ 36.39万 - 项目类别:
相似海外基金
Life outside institutions: histories of mental health aftercare 1900 - 1960
机构外的生活:1900 - 1960 年心理健康善后护理的历史
- 批准号:
DP240100640 - 财政年份:2024
- 资助金额:
$ 36.39万 - 项目类别:
Discovery Projects
Development of a program to promote psychological independence support in the aftercare of children's homes
制定一项计划,促进儿童之家善后护理中的心理独立支持
- 批准号:
23K01889 - 财政年份:2023
- 资助金额:
$ 36.39万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Integrating Smoking Cessation in Tattoo Aftercare
将戒烟融入纹身后护理中
- 批准号:
10452217 - 财政年份:2022
- 资助金额:
$ 36.39万 - 项目类别:
Integrating Smoking Cessation in Tattoo Aftercare
将戒烟融入纹身后护理中
- 批准号:
10670838 - 财政年份:2022
- 资助金额:
$ 36.39万 - 项目类别:
Aftercare for young people: A sociological study of resource opportunities
年轻人的善后护理:资源机会的社会学研究
- 批准号:
DP200100492 - 财政年份:2020
- 资助金额:
$ 36.39万 - 项目类别:
Discovery Projects
Creating a National Aftercare Strategy for Survivors of Pediatric Cancer
为小儿癌症幸存者制定国家善后护理策略
- 批准号:
407264 - 财政年份:2019
- 资助金额:
$ 36.39万 - 项目类别:
Operating Grants
Aftercare of green infrastructure: creating algorithm for resolving human-bird conflicts
绿色基础设施的善后工作:创建解决人鸟冲突的算法
- 批准号:
18K18240 - 财政年份:2018
- 资助金额:
$ 36.39万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of an aftercare model for children who have experienced invasive procedures
为经历过侵入性手术的儿童开发善后护理模型
- 批准号:
17K12379 - 财政年份:2017
- 资助金额:
$ 36.39万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of a Comprehensive Aftercare Program for children's self-reliance support facility
为儿童自力更生支持设施制定综合善后护理计划
- 批准号:
17K13937 - 财政年份:2017
- 资助金额:
$ 36.39万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Project#2 Extending Treatment Effects Through an Adaptive Aftercare Intervention
项目
- 批准号:
8742767 - 财政年份:2014
- 资助金额:
$ 36.39万 - 项目类别: